Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

Expression and functional characterization of membrane-integrated mammalian corticotropin releasing factor receptors 1 and 2 in Escherichia coli.

Jappelli R, Perrin MH, Lewis KA, Vaughan JM, Tzitzilonis C, Rivier JE, Vale WW, Riek R.

PLoS One. 2014 Jan 17;9(1):e84013. doi: 10.1371/journal.pone.0084013. eCollection 2014.

2.

A soluble form of the first extracellular domain of mouse type 2beta corticotropin-releasing factor receptor reveals differential ligand specificity.

Perrin MH, DiGruccio MR, Koerber SC, Rivier JE, Kunitake KS, Bain DL, Fischer WH, Vale WW.

J Biol Chem. 2003 May 2;278(18):15595-600. Epub 2003 Feb 28.

5.

Exploring the binding site crevice of a family B G protein-coupled receptor, the type 1 corticotropin releasing factor receptor.

Gkountelias K, Papadokostaki M, Javitch JA, Liapakis G.

Mol Pharmacol. 2010 Oct;78(4):785-93. doi: 10.1124/mol.110.065474. Epub 2010 Jul 27.

6.

Structure of the N-terminal domain of a type B1 G protein-coupled receptor in complex with a peptide ligand.

Grace CR, Perrin MH, Gulyas J, Digruccio MR, Cantle JP, Rivier JE, Vale WW, Riek R.

Proc Natl Acad Sci U S A. 2007 Mar 20;104(12):4858-63. Epub 2007 Mar 12.

7.

Structure-function relationship of different domains of the rat corticotropin-releasing factor receptor.

Sydow S, Radulovic J, Dautzenberg FM, Spiess J.

Brain Res Mol Brain Res. 1997 Dec 15;52(2):182-93.

PMID:
9495539
9.

Ligand affinity for amino-terminal and juxtamembrane domains of the corticotropin releasing factor type I receptor: regulation by G-protein and nonpeptide antagonists.

Hoare SR, Sullivan SK, Schwarz DA, Ling N, Vale WW, Crowe PD, Grigoriadis DE.

Biochemistry. 2004 Apr 6;43(13):3996-4011.

PMID:
15049707
10.

Human CRF2 alpha and beta splice variants: pharmacological characterization using radioligand binding and a luciferase gene expression assay.

Ardati A, Goetschy V, Gottowick J, Henriot S, Valdenaire O, Deuschle U, Kilpatrick GJ.

Neuropharmacology. 1999 Mar;38(3):441-8.

PMID:
10219982
11.

Impact of N-terminal domains for corticotropin-releasing factor (CRF) receptor-ligand interactions.

Klose J, Fechner K, Beyermann M, Krause E, Wendt N, Bienert M, Rudolph R, Rothemund S.

Biochemistry. 2005 Feb 8;44(5):1614-23.

PMID:
15683245
12.

Conformational states of the corticotropin releasing factor 1 (CRF1) receptor: detection, and pharmacological evaluation by peptide ligands.

Hoare SR, Sullivan SK, Pahuja A, Ling N, Crowe PD, Grigoriadis DE.

Peptides. 2003 Dec;24(12):1881-97.

PMID:
15127940
14.

Characterization of a Pachymedusa dacnicolor-Sauvagine analog as a new high-affinity radioligand for corticotropin-releasing factor receptor studies.

Perrin MH, Tan LA, Vaughan JM, Lewis KA, Donaldson CJ, Miller C, Erchegyi J, Rivier JE, Sawchenko PE.

J Pharmacol Exp Ther. 2015 May;353(2):307-17. doi: 10.1124/jpet.114.222307. Epub 2015 Mar 3.

15.

Alanine scanning mutagenesis of the second extracellular loop of type 1 corticotropin-releasing factor receptor revealed residues critical for peptide binding.

Gkountelias K, Tselios T, Venihaki M, Deraos G, Lazaridis I, Rassouli O, Gravanis A, Liapakis G.

Mol Pharmacol. 2009 Apr;75(4):793-800. doi: 10.1124/mol.108.052423. Epub 2009 Jan 5.

16.

Evidence that corticotropin-releasing factor receptor type 1 couples to Gs- and Gi-proteins through different conformations of its J-domain.

Berger H, Heinrich N, Wietfeld D, Bienert M, Beyermann M.

Br J Pharmacol. 2006 Dec;149(7):942-7. Epub 2006 Oct 23.

17.

Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor.

Lewis K, Li C, Perrin MH, Blount A, Kunitake K, Donaldson C, Vaughan J, Reyes TM, Gulyas J, Fischer W, Bilezikjian L, Rivier J, Sawchenko PE, Vale WW.

Proc Natl Acad Sci U S A. 2001 Jun 19;98(13):7570-5.

18.

Juxtamembrane region of the amino terminus of the corticotropin releasing factor receptor type 1 is important for ligand interaction.

Assil IQ, Qi LJ, Arai M, Shomali M, Abou-Samra AB.

Biochemistry. 2001 Feb 6;40(5):1187-95.

PMID:
11170443
19.

125I-Tyro-sauvagine: a novel high affinity radioligand for the pharmacological and biochemical study of human corticotropin-releasing factor 2 alpha receptors.

Grigoriadis DE, Liu XJ, Vaughn J, Palmer SF, True CD, Vale WW, Ling N, De Souza EB.

Mol Pharmacol. 1996 Sep;50(3):679-86.

PMID:
8794910
20.

Evidence for the abundant expression of arginine 185 containing human CRF(2alpha) receptors and the role of position 185 for receptor-ligand selectivity.

Dautzenberg FM, Huber G, Higelin J, Py-Lang G, Kilpatrick GJ.

Neuropharmacology. 2000 Jun 8;39(8):1368-76.

PMID:
10818253

Supplemental Content

Support Center